Drs Singal and Lewandowski review use of tyrosine kinase inhibitors, sorafenib and lenvatinib, and discuss trials that combined systemic therapy with chemoembolization.
Frontline Pembrolizumab Plus Trastuzumab/Chemo Meets OS End Point in HER2+ Gastric/GEJ Cancer
D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
FDA Approves Trastuzumab-strf for HER2-Overexpressing Breast and Gastric/GEJ Cancer
Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent
FDA Approves Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs
Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma